Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

siRNA

ALN-PCSsc, first-in-class PCSK9 RNA interference therapeutic advances to Phase II

ALN-PCSsc, first-in-class PCSK9 RNA interference therapeutic advances to Phase II

ALN-PCSsc, first-in-class PCSK9 RNA interference therapeutic advances to Phase II ALN-PCSsc a novel PCSK9 therapeutic that blocks PCSK9 synthesis in the liver, has now entered Phase II development, with the launch of the ORION-1 study. This study aims to enrol 480 patients with atherosclerotic cardiovascular…

read more »